No effect from double‐blind trial of physostigmine and lecithin in Alzheimer disease

Publisher Website
Google Scholar
Abstract
Eight patients with clinically diagnosed mild to severe Alzheimer disease were treated during two six-week periods by a double-blind, single-crossover protocol with placebo or a combination of 18 gm of lecithin and 3 to 10 mg of oral physostigmine daily. No improvement in behavior, recent memory, or other neuro psychological functions occurred.